Scoop: A Penn Parkin­son's spin­out goes dark as ex-FDA com­mish Hahn jumps off board

Not even a for­mer FDA com­mis­sion­er could keep this small biotech alive. Neu­rol­o­gy-fo­cused Black­fynn, a 2015 Penn spin­out, has gone dark, End­points News has learned …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER